Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: A prospectively randomized cross-over study

Pediatric Blood and Cancer

Volumn 61, Issue 2, 2014, Pages 297-301

  Mikkelsen, Torben Stamm ^a   Mamoudou, Aissata Diop ^a   Tuckuviene, Ruta ^b   Wehner, Peder Skov ^c   Schroeder, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Drug clearance; Hydration; Methotrexate; Nephrotoxicity; Pharmacokinetics

Indexed keywords

BICARBONATE; CREATININE; FOLINIC ACID; GLUCOSE; METHOTREXATE; POTASSIUM CHLORIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FLUID THERAPY; HUMAN; HYDRATION; INFANT; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; YOUNG ADULT;

EID: 84890884746     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24623     Document Type: Article

References (24)

1. Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2009.
2. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2009.
3. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: A review. Br J Haematol 2009; 146:489-503.
4. Rask C, Albertioni F, Bentzen SM, et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia-A logistic regression analysis. Acta Oncol 1998; 37:277-284.
5. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12:1667-1672.
6. Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20:1955-1962.
7. Sasaki K, Tanaka J, Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol 1984; 13:9-13.
8. Kinoshita A, Kurosawa Y, Kondoh K, et al. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2003; 51:256-260.
9. Christensen ML, Rivera GK, Crom WR, et al. Effect of hydration on methotrexate plasma concentrations in children with acute lymphocytic leukemia. J Clin Oncol 1988; 6:797-801.
10. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981; 19:453-456.
11. Aumente D, Buelga DS, Lukas JC, et al. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 2006; 45:1227-1238.
12. Joannon P, Oviedo I, Campbell M, et al. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: Lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004; 43:17-22.
13. Kovacs GT, Paal C, Somlo P, et al. Proteinuria due to suboptimal hydration with high-dose methotrexate therapy. Cancer Chemother Pharmacol 1993; 33:262-263.
14. Isoda T, Ito S, Kajiwara M, et al. Successful high-dose methotrexate chemotherapy in a patient with acute lymphocytic leukemia who developed acute renal failure during the initial treatment. Pediatr Int 2007; 49:1018-1019.
15. Declaration of Helsinki: ethical principles for medical research involving human subjects. Ferney-Voltaire, France: World Medical Association; 2010. Available at http://www.wma.net/en/30publications/10policies/b3/index.html
16. Evans WE, Pratt CB, Taylor RH, et al. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979; 3:161-166.
17. Isacoff WH, Morrison PF, Aroesty J, et al. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 1977; 61:1665-1674.
18. Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297:630-634.
19. Tattersall MHN, Parker LM, Pitman SW, et al. Clinical pharmacology of high-dose methotrexate (NSC-740). Cancer Chemother Rep 1975; 6:25-29.
20. van Kooten Niekerk PB, Schmiegelow K, Schroeder H. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol 2008; 81:391-398.
21. Skarby T, Jonsson P, Hjorth L, et al. High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 2003; 51:311-320.
22. Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27:5972-5978.
23. Rau T, Erney B, Gores R, et al. High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 2006; 80:468-476.
24. Ramsey LB, Bruun GH, Yang W, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012; 22:1-8.